Cartesian Therapeutics (RNAC) Cash from Investing Activities (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Cash from Investing Activities of -$27000.0 for Q1 2026, up 97.49% year-over-year from -$13671.7 in Q1 2025, and up 94.51% quarter-over-quarter from -$492000.0 in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Cash from Investing Activities for 12 consecutive years, with -$27000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 97.49% year-over-year to -$27000.0; the TTM figure through Mar 2026 stood at -$4.4 million (up 52.19% YoY), while the FY2025 annual figure was -$5.5 million, up 37.61% from the prior year.
- Cash from Investing Activities grew to -$27000.0 in Q1 2026 per RNAC's latest filing, from -$492000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $28.1 million in Q1 2023 and bottomed at -$29.9 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged $336500.0 across 5 years, with a median of -$423000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 194.65% — and 2024, when it tumbled 13125.0%.
- Cartesian Therapeutics' Cash from Investing Activities stood at $5.5 million in 2022, then increased by 18.36% to $6.5 million in 2023, then slumped by 105.45% to -$354000.0 in 2024, then sank by 38.98% to -$492000.0 in 2025, then soared by 94.51% to -$27000.0 in 2026.
- Business Quant data shows RNAC's Cash from Investing Activities at -$27000.0 in Q1 2026, -$492000.0 in Q4 2025, and -$1.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | -272,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -272,000.00 |
| Mar 31, 2026 | -27,000.00 |
| Dec 31, 2025 | -492,000.00 |
| Sep 30, 2025 | -1.29 Mn |
| Jun 30, 2025 | -2.60 Mn |
| Mar 31, 2025 | -1.08 Mn |
| Dec 31, 2024 | -354,000.00 |
| Sep 30, 2024 | -6.20 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Mar 31, 2024 | -602,000.00 |
| Dec 31, 2023 | 6.50 Mn |
| Jun 30, 2023 | -12,000.00 |
| Mar 31, 2023 | 28.12 Mn |
| Dec 31, 2022 | 5.49 Mn |
| Sep 30, 2022 | -29.94 Mn |
| Jun 30, 2022 | -99,000.00 |
| Mar 31, 2022 | 9.55 Mn |
| Dec 31, 2021 | 9.72 Mn |
| Sep 30, 2021 | -1.80 Mn |
| Jun 30, 2021 | -2.62 Mn |